Hexarelin, a synthetic hexapeptide growth hormone secretagogue
CAS 140703-51-1 This CAS number is reported directly by Krause Analytical for the tested Hexarelin sampleC₄₇H₅₈N₁₂O₆Approximately 887.0 g/molLinear peptideLyophilized powder
$79.00–$629.00Price range: $79.00 through $629.00
UPS Ground $9.95. Free at $150. Orders before 2 pm ET ship the same business day.
Lot 2026/02 · Krause Analytical · reported 22 May 2026 . The bar shows where the reported result falls against Astramide’s published release criterion. The notch marks the criterion.
Within criterionAbove criterionNot on this COA
Test
Method
Criterion
Result
Result vs criterion
Status
Identity
HPLC-UV-MS
Mass spectral match to the labelled compound
Confirmed
WITHIN SPEC
Chromatographic purity
HPLC-UV/MS
at or above 98.0%
99.6 %
95at or above 98.0%100
WITHIN SPEC
Net content
HPLC-UV-MS
9.5 mg
80120
REPORTED
Endotoxin
LAL, USP <85>
below 0.5 EU/mL
<0.5 EU/mL
WITHIN SPEC
Values are reported per vial or bottle unless otherwise noted. Every figure here is taken from the batch Certificate of Analysis and nothing else.
Krause Analytical · 3 pages · served inline, not a screenshot
Quick reference
How to read this report
Same six keys on every Astramide product page. Only the values change.
1Lot numberMatch it to the number printed on your product label. If they differ, this report is not for your product.
2IdentityMass spectrometry confirms the molecule is the one on the label. It conforms or it does not. There is no partial result.
3Chromatographic purityThe share of the material that is the target peptide. A purity figure quoted without a method is not a purity figure.
4Net contentHow much compound is in each vial or bottle, as measured by the laboratory. A different question from purity.
5EndotoxinMeasured against a ceiling, not a floor. Sensitivity differs by laboratory, so results are not compared across labs.
6Laboratory, method, dateWho ran it, on what instrument, and when. A report with no named laboratory or no date is not a report.
Molecular profile
Hexarelin, in structural terms.
Sequence
His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂
Published human research describes Hexarelin using this six-residue sequence.
Molecular formula
C₄₇H₅₈N₁₂O₆
Molecular weight
Approximately 887.0 g/mol
CAS number
140703-51-1 This CAS number is reported directly by Krause Analytical for the tested Hexarelin sample
Structure type
Linear peptide
Primary molecular target
Growth Hormone Secretagogue Receptor (GHSR / GHS-R1a) Hexarelin belongs to the growth hormone secretagogue family and acts through specific GHS receptors at pituitary and hypothalamic sites. Additional research has examined peripheral Hexarelin-binding sites, including CD36-associated signaling in cardiovascular systems, but GHSR remains the primary endocrine target relevant to GH secretagogue research.
Hexarelin is a synthetic six-residue growth hormone secretagogue with the sequence His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂. The structure incorporates D-amino-acid residues and a 2-methyl-tryptophan substitution designed to produce a stable growth hormone-releasing peptide analog. Early pharmacological studies describe it as a potent GHRP-family secretagogue.PubChem lists this formula for Examorelin / Hexarelin and reports a monoisotopic molecular weight of approximately 886.46 Da.
Hexarelin is a synthetic growth hormone secretagogue that stimulates growth hormone release through growth hormone secretagogue receptor-associated signaling at pituitary and hypothalamic sites.
Its mechanism differs from that of GHRH analogs. Rather than directly targeting the GHRH receptor, Hexarelin belongs to the GHS/ghrelin-receptor signaling class. Human and animal studies have demonstrated growth-hormone release following Hexarelin exposure.
Research has also demonstrated GHSR-1a expression changes in hypothalamic and pituitary tissues following Hexarelin exposure, further supporting its relevance to GHSR-associated endocrine signaling.
Separate preclinical studies have investigated cardiovascular effects and peripheral binding sites, including CD36-associated mechanisms. Those peripheral findings should be distinguished from Hexarelin's principal endocrine GHSR activity.
These are published research systems. They do not describe approved clinical applications, and they do not establish efficacy or safety in humans.
Cited literature
Imbimbo BP et al., 1994. Growth hormone-releasing activity of hexarelin in humans. A dose-response study. Eur J Clin Pharmacol. PMID 7957536. https://pubmed.ncbi.nlm.nih.gov/7957536/
Arvat E et al., 1997. Hexarelin, a synthetic growth-hormone releasing peptide, shows no interaction with corticotropin-releasing hormone and vasopressin on adrenocorticotropin and cortisol secretion in humans. Neuroendocrinology. PMID 9430449. https://pubmed.ncbi.nlm.nih.gov/9430449/
Maccario M et al., 2002. Impact of two or three daily subcutaneous injections of hexarelin, a synthetic growth hormone (GH) secretagogue, on 24-h GH, prolactin, adrenocorticotropin and cortisol secretion in humans. Eur J Endocrinol. PMID 11888836. https://pubmed.ncbi.nlm.nih.gov/11888836/
Papotti M et al., 2000. Growth hormone secretagogue binding sites in peripheral human tissues. J Clin Endocrinol Metab. PMID 11061542. https://pubmed.ncbi.nlm.nih.gov/11061542/
Bresciani E et al., 2004. Hexarelin modulates the expression of growth hormone secretagogue receptor type 1a mRNA at hypothalamic and pituitary sites. Neuroendocrinology. PMID 15361691. https://pubmed.ncbi.nlm.nih.gov/15361691/
Evidence level
Extensive published literature Hexarelin appears widely in the published growth hormone secretagogue literature, spanning receptor-binding, cellular and animal-model studies of GH-axis signalling. Astramide supplies this material for laboratory research use only.
Handling and storage
As supplied
Lyophilized powder in a sealed vial. Held in laboratory-rated freezers from arrival to shipment.
Storage
Store per the conditions printed on the vial label. Avoid heat, moisture and repeated temperature cycling.
Handling
For qualified professionals in controlled laboratory environments, following validated laboratory procedures.
Frequently asked questions
About this compound and its batch data.
What purity did this Hexarelin Acetate batch achieve?
Lot 2026/02 was analysed by Krause Analytical and returned chromatographic purity of 99.6% by HPLC with UV detection coupled to mass spectrometry. Identity was confirmed by mass spectral match. The full certificate is published on this page, and every figure shown here is taken from it.
How much Hexarelin Acetate is in the vial?
The laboratory measured 9.5 mg against a 10 mg label claim, which is 95.4% of label. Net content is reported on a per-vial basis. Astramide publishes the measured figure rather than the label claim, whether it falls above or below.
Was this Hexarelin Acetate batch tested for endotoxins?
Yes. Endotoxin testing was performed using the Limulus Amebocyte Lysate assay in accordance with USP <85>, and this batch returned <0.5 EU/mL. The result appears on the certificate published on this page.
How should Hexarelin Acetate be stored for research use?
As supplied, the lyophilized powder should be held at -20°C and protected from light and moisture. Once reconstituted, store at 2-8°C and use within 14 to 30 days. Avoid repeated freeze-thaw cycles and follow the handling procedures appropriate to your laboratory.
What is the difference between research-grade and pharmaceutical-grade Hexarelin Acetate?
These are separate classifications. Research-grade material is supplied for laboratory research use only and is not intended for human or animal consumption. Pharmaceutical-grade is an FDA classification that applies to drugs manufactured for human use. Astramide supplies research-grade material only.
How can I verify this Hexarelin Acetate certificate independently?
The certificate was issued by Krause Analytical under lot 2026/02, laboratory reference 205071. Quote that reference to the laboratory directly. The same document is published here in full, and is not summarised or reformatted by Astramide.
Research use only
This product is intended strictly for in-vitro laboratory research conducted by qualified professionals.
It is not intended for human or animal consumption, clinical use, or therapeutic application.
The statements on this page have not been reviewed by the FDA. These research peptides are not intended
to diagnose, treat, cure, or prevent any disease. Research Use Only.
Get It Now
This product has multiple variants. The options may be chosen on the product page
Added to your cart
Your cart is empty.
Your Privacy Choices
We use analytics and advertising tools to understand how visitors find us and which campaigns work. You can turn either off. Your choice is saved in this browser.
AnalyticsGoogle Analytics, Microsoft Clarity and order source tracking. Helps us see how the site is used and fix problems.
Off (browser signal)
AdvertisingMeta and X pixels, and server-side events. Opting out also opts you out of "sharing" and targeted advertising under state privacy laws.
Off (browser signal)
Your browser is sending a Global Privacy Control signal, so analytics and advertising are off. To change this, turn off the signal in your browser settings.
Strictly necessary cookies (cart, sign-in, checkout, entry acknowledgment) always stay on. See our Privacy Policy.
Know what's in it before you order.
Every Astramide batch is tested by an independent US lab. The report goes public before the batch goes on sale, so you can check the numbers first.
Independent US lab test on every batch
Full report published before it goes on sale
Kept frozen, shipped from Austin, Texas
GLP-3RLot 2026/02 · May 8, 2026
>99.9%purity by HPLC-UV/MS
90%Minimum 98.0%100%
Identity: Confirmed by mass specEndotoxin: Below 0.5 EU/mL
Pro Series